Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares Outstanding
Ratios

Acro Biomedical (ACBM) Gross Profit (2017 - 2022)

Acro Biomedical has reported Gross Profit over the past 6 years, most recently at $64000.0 for Q4 2022.

  • Quarterly results put Gross Profit at $64000.0 for Q4 2022, down 57.33% from a year ago — trailing twelve months through Sep 2023 was $64000.0 (down 71.74% YoY), and the annual figure for FY2022 was $140500.0, down 45.86%.
  • Gross Profit for Q4 2022 was $64000.0 at Acro Biomedical, down from $76500.0 in the prior quarter.
  • Over the last five years, Gross Profit for ACBM hit a ceiling of $252600.0 in Q3 2018 and a floor of $12096.0 in Q4 2019.
  • Median Gross Profit over the past 5 years was $135400.0 (2018), compared with a mean of $126890.9.
  • Biggest five-year swings in Gross Profit: plummeted 91.07% in 2019 and later soared 159.32% in 2022.
  • Acro Biomedical's Gross Profit stood at $135400.0 in 2018, then plummeted by 91.07% to $12096.0 in 2019, then surged by 1217.82% to $159404.0 in 2020, then dropped by 5.9% to $150000.0 in 2021, then tumbled by 57.33% to $64000.0 in 2022.
  • The last three reported values for Gross Profit were $64000.0 (Q4 2022), $76500.0 (Q1 2022), and $150000.0 (Q4 2021) per Business Quant data.